Endo Open To Settlement In US Vasostrict Showdown
Eagle Strongly Suggested ‘At-Risk’ Launch Is Possible
Endo is leaving the door wide open to settle its patent-litigation showdown with Eagle Pharmaceuticals over Vasostrict (vasopressin), after Eagle said it was mulling an ‘at-risk’ launch.
You may also be interested in...
Following the disappointment of a complete response letter and delayed trial proceedings, Eagle has secured FDA approval for the first generic version of Par’s Vasostrict, which is tipped to have branded sales approaching $1bn in the US in 2021.
Eagle Pharmaceuticals has celebrated a US court ruling that clears the way for it to launch its generic vasopressin rival to Endo’s Vasostrict. However, the company is still waiting for FDA approval after its application was delayed by a CRL earlier this year, with a new action date provided by the agency.
Endo’s non-injectable Generics revenues plunged by 28% in Q1, in part due to competitive challenges in the US generics sector that management said would continue through 2021.